Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-10
2005-05-10
Jones, Dwayne (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S315000, C514S317000, C514S330000, C514S345000, C514S381000, C514S556000
Reexamination Certificate
active
06890931
ABSTRACT:
Compositions and uses of mGluR5 antagonists for the treatment and prevention of neurological disorders, such as Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome, are disclosed.
REFERENCES:
patent: WO 0024395 (2000-05-01), None
patent: WO 0062771 (2000-10-01), None
patent: WO 0102342 (2001-01-01), None
patent: WO 0110846 (2001-02-01), None
patent: WO 0112627 (2001-02-01), None
patent: WO 0114390 (2001-03-01), None
Grauer, S. M. et al., Psychopharmacology, vol. 141, No. 4, pp. 405-412, Feb. 1999.*
Varney, M. A. et al., “SIB-1757 and SIB-1893: Selective, Noncompetitive Antagonists of Metabotrophic Glutamate Receptor Type 5”, Journal of Pharmacology and Experimental Therapeutics, vol. 290, No. 1, pp 170-181, 1999.*
O'Leary, D. M., et al., “Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA antagonism”, British Journal of Pharmacology, 131, pp 1429-1437, 2000.*
Weiler, I. J. et al., “Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation”,Proc. Natl. Acad. Sci., vol. 94, pp 5395-5400, May 1997.*
Spooren, W.P.J.M., et al., “Novel Allosteric Antagonists Shed Light on mglu5Receptors and CNS Disorders,”TRENDS in Pharmacological Sciences22(7):331-337 (2001).
Pepeu, G., “Memory Disorders: Novel Treatments, Clinical Perspective,”Life Sciences. 55(25/26) :2189-2194 (1994).
Bartus, R. T., “Drugs to Treat Age-Related Neurodegenerative Problems: The Final Frontier of Medical Science?”J. Am. Geriatr. Soc.38(6) : 680-695 (1990).
Bordi, F., et al., “Group I Metabotropic Glutamate Receptors: Implications for Brain Disease”,Prog. Neurobiol., 59(1) :55-79 (1999).
Knöpfel, T., et al., “Metabotropic Glutamate Receptors: Novel Targets for Drug Development”,J. Med. Chem., 38(9) :1417-1426 (1995).
Oka A., et al., “The Up-regulation of Metabotropic Glutamate Receptor 5 (mGluR5) in Down's Syndrome Brains,”Acta Neuropathol., 97(3) :275-278 (1999).
Greenough, W.T. et al., “Synaptic Regulation of Protein Synthesis and the Fragile X Protein,”Proc. Natl. Acad. Sci. USA, 98(13) :7101-7106 (2001).
Grauer, S.M. et al., “IntracerEbral Administration of Metabotropic Glutamate Receptor Agonists Disrupts Prepulse Inhibition of Acoustic Startle in Sprague-Dawley Rats,”Psychopharmacology, 141:405-412 (1999).
Snyder, E.M., et al., “Internalization of Ionotropic Glutamate Receptors in Response to mGluR Activation,”Nature Neurosci., 4(11):1079-1085 (2001).
Huber, K.M., et al., “Role for Rapid Dendritic Protein Synthesis in HippOcampal mGluR-Dependent Long-Term Depression,”Science288:1254-1256 (2000).
Bear Mark F.
Huber Kimberly M.
Warren Stephen T.
Brown University
Emory University
Hamilton Brook Smith & Reynolds P.C.
Jones Dwayne
LandOfFree
Methods of treating disorders with group I mGluR antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating disorders with group I mGluR antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating disorders with group I mGluR antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3433933